3-Jan-2025
No headlines found.
Globe Newswire (Tue, 3-Dec 4:01 PM ET)
Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference
Globe Newswire (Tue, 26-Nov 4:01 PM ET)
Globe Newswire (Mon, 11-Nov 5:00 AM ET)
Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights
Globe Newswire (Thu, 7-Nov 4:01 PM ET)
Tectonic Therapeutic to Present Phase 1a Data at AHA 2024
Globe Newswire (Tue, 22-Oct 4:01 PM ET)
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease.
Tectonic Therapeutic trades on the NASDAQ stock market under the symbol TECX.
As of January 3, 2025, TECX stock price climbed to $48.52 with 114,895 million shares trading.
TECX has a beta of 1.31, meaning it tends to be more sensitive to market movements. TECX has a correlation of 0.06 to the broad based SPY ETF.
TECX has a market cap of $715.80 million. This is considered a Small Cap stock.
The top ETF exchange traded funds that TECX belongs to (by Net Assets): VTI, DWAS, VXF, IBB, IWC.
TECX support price is $43.40 and resistance is $47.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TECX shares will trade within this expected range on the day.